MARIZYME, INC.
MARIZYME, INC. (MRZM): 6 pipeline candidates. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E -2.37 · 0% dilution
Lead: BLA Filed
6 candidates
N/A
N/A
A transparent, data-derived signal for MARIZYME, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$40K
Cash
—
Quarterly Burn
$983K
Runway
—
Revenue
$0
Pipeline (6 candidates)
Frequently asked questions
How many drug candidates are in MARIZYME, INC.'s pipeline?
MARIZYME, INC. (MRZM) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MARIZYME, INC.'s lead drug candidate?
MARIZYME, INC.'s most advanced tracked candidate is duragraft (BLA Filed) for Cardiac bypass, peripheral bypass, and other vascular surgeries.
What is MARIZYME, INC.'s market capitalization?
MARIZYME, INC.'s market capitalization is approximately $40K.
Who is the CEO of MARIZYME, INC.?
Mr. David L. Barthel M.B.A. is the chief executive officer of MARIZYME, INC. (MRZM).
Get the full picture on MARIZYME, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.